View all stories with this category.
Big company buyouts are more about immediate gains and rarely consider the impact on research, says Derek Lowe
It takes more than random stumbling to find new reactions, says Derek Lowe
New molecules with unpredictable biological activity deserve sensible amounts of respect, says Derek Lowe
Derek Lowe wonders what the most life-changing instrument for organic chemists is, and what might be missing from the toolbox
Derek Lowe thinks the Devil’s R&D management schemes might be scarily familiar
Derek Lowe ponders whether anything is truly ‘undruggable’ if we look in the right places
Is Derek Lowe troubled by his failure to develop a compound that has made it to the pharmacy shelf?
Redesigning nature’s catalysts is tantalising but tricky, says Derek Lowe
Not every reaction can be run in a bucket, says Derek Lowe, but there are limits to what should be classed as ‘useful’
Keeping up with the literature is impossible, says Derek Lowe.
Derek Lowe wonders whether we should mourn the decline of classic analytical techniques or embrace technological advances
How long should scientists stay at the bench, asks Derek Lowe. How long is a piece of string?
Knowing a drug’s exact biochemistry has never been a prerequisite for approval, says Derek Lowe, and nor should it be
A can-do attitude and some lateral thinking can save time and money when it comes to exotic apparatus, says Derek Lowe
Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?
It’s more a research problem, than a commercial one, says Derek Lowe
Derek Lowe investigates the long running tradition of naming reactions after their inventors
How do you reconcile the need for personal safety with unfamiliar compounds, asks Derek Lowe
The pharma industry should be more open with its trial data, says Derek Lowe
Derek Lowe examines an alternative funding model for pharmaceutical research
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud